期刊文献+

氨溴索对慢阻肺患者肺功能的影响观察 被引量:16

下载PDF
导出
摘要 慢性阻塞性肺疾病(慢阻肺)以气道、肺实质和肺血管的慢性炎症为特征,逐渐削弱患者的呼吸功能,造成患者呼吸困难,而且往往逐渐加重,影响患者的生活及工作,需要积极治疗。因该疾病在临床较为常见,其治疗方案已经比较规范,但是该类患者容易反复,临床工作者一直在探求更佳的治疗药物。笔者借助本研究观察氨溴索对慢阻肺患者肺功能的影响,为临床治疗用药提供参考依据,本文将相关病例资料进行总结分析如下。
作者 郑天燕
出处 《河北医药》 CAS 2013年第10期1537-1538,共2页 Hebei Medical Journal
  • 相关文献

参考文献6

二级参考文献27

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2冉丕鑫 王辰 姚婉贞 等.我国部分地区慢性阻塞性肺疾病流行病学研究[J].中华结核和呼吸杂志,2007,.
  • 3GOLD Executive Committee[DB/OL]. Guidelines: Global Strategy for Diagnosis, Management, and Prevention of COPD,November 2006 [ 2006-11-18 ]. http://www.goldcopd.com/Guidelineitem. asp? 11 =2&12 = 1&intId =989.
  • 4Celli BR, MacNee W, Committee members. Standard for the diagnosis and treatment of patients with COPD : a summary of the ATS/ERS position paper. Eur Respir J, 2004,23:932-946.
  • 5Celli BR, Cote CG, Matin JM, et al. The body mass index,airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 2004,350 : 1005-1012.
  • 6Yamamoto Y,Gaynor RB. Therapeutic potential of inhabition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest ,2001,107 : 135-142.
  • 7Noguera A, Sala E, Pons AR, et al. Expression of adhesion molecules during apoptosis of circulating neutropbils in COPD. Chest ,2004,125 : 1837-1842.
  • 8Rogers DF. Mucus hyper secretion in chronic obstructive pulmonary disease. Novartis Found Symp,2001,234 :65-77.
  • 9Di Stefano A, Caramori G, Oates T, et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J, 2002,20: 556-563.
  • 10Barnes PJ ,Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J ,2003,22:672-688.

共引文献1813

同被引文献122

  • 1慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志(电子版),2014,6(2):67-80. 被引量:2049
  • 2邱骏,郭玉娜,钟蕙芳.妇科腹腔镜手术73例并发症的临床分析[J].实用妇产科杂志,2010,26(3):212-215. 被引量:38
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8235
  • 4陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 5蔡柏蔷,李龙芸.协和呼吸病学[M].2版.北京:中国协和医科大学出版社,2010:1115-1159.
  • 6Grigor'eva NIu,Kuznetsov AN,Koroleva TV,et al.The combined drug ascoril in the treatment of patients with chronic obstructive pulmonary disease concurrent with coronary heart disease[J].Ter Arkh,2013,85(8):91-94.
  • 7Refai M,Brunelli A,XiuméF,et al.Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy:a randomized trial[J].Eur J Cardiothorac Surg,2009,35(3):469-473.
  • 8Beeh KM,BeierJ,Esperester A,et al.Antiinflamatory properties of ambroxol[J].Eur J Med Res,2008,13(12) ,557-562.
  • 9Malerba M, Racnoli B.Ambroxol in the 21^st century : phar- macological and clinical update[J].Expert Opin Drug Metab Toxicol, 2008,4 (8) : 1119-1129.
  • 10Gibbs BF, Schmutzle W,Vollrath IB,et al.Ambroxol inhibits the release of histamine,leukotrienes and cytokines from human leukocytes and mast cells[J].Inflamm Res, 1999,48 (2):86-93.

引证文献16

二级引证文献165

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部